• About us
• Contact

Advertisement

Organisation › Details

AstraZeneca (Group)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. *

 

	Start	1999-04-05 merged
	Predecessor	Zeneca (Group)
	Industry	pharmaceutical
	Person	Soriot, Pascal (AstraZeneca 201210– CEO before Roche COO Pharma Div before Genentech CEO)
	Person 2	Dunoyer, Marc (AstraZeneca 201311– CFO joined 201303 as EVP Global Portfolio + Product Strategy before GSK)
	Region	Cambridge, Cambridgeshire
	Country	United Kingdom (GB)
	Street	1 Francis Crick Avenue Cambridge Biomedical Campus
	City	CB2 0AA Cambridge, Cambridgeshire
		Address record changed: 2022-11-29
Basic data	Employees	I: 50,001 to 100,0 (2019-12-31)
	Currency	USD
	Annual sales	24,384,000,000 (revenue, total, consolidated (2019) 2019-12-31)
	Profit	1,227,000,000 (2019-12-31)
	Cash	5,369,000,000 (2019-12-31)
		* Document for »About Section«: AstraZeneca plc. (11/29/22). "Press Release: AstraZeneca to Acquire Neogene Therapeutics, Accelerating Ambition in Oncology Cell Therapy".
		Record changed: 2023-08-22

Advertisement

More documents for AstraZeneca (Group)

• [1] Nanoform Finland Oyj. (10/23/23). "Press Release: Nanoform Grant Global Starmap AI License to AstraZeneca". Helsinki....
• [2] AstraZeneca plc. (9/20/23). "Press Release: Alexion Completes Purchase and Licence Agreement for Early-stage Rare Disease Gene Therapy Portfolio from Pfizer"....
• [3] Verge Analytics, Inc. (d/b/a Verge Genomics). (9/8/23). "Press Release: Verge Genomics Announces Artificial Intelligence-enabled Drug Discovery Collaboration with Alexion for Rare Neurodegenerative and Neuromuscular Diseases". South San Francisco, CA....
• [4] Bico Group AB. (8/21/23). "Press Release: Maria Forss Is Appointed New President and CEO of Bico Group AB (publ)"....
• [5] SandboxAQ. (6/22/23). "Press Release: SandboxAQ Announces Biopharma Molecular Simulation Division to Speed Life-Saving Drugs to Patients Through AI and Quantum Solutions". Palo Alto, CA....
• [6] Pieris Pharmaceuticals, Inc.. (6/21/23). "Press Release: Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study". Boston, MA....
• [7] Quell Therapeutics Ltd.. (6/9/23). "Press Release: Quell Therapeutics Signs a Collaboration, Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases". London...
• [8] Transgene S.A.. (5/5/23). "Press Release: Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio". Strasbourg....
• [9] Personalis, Inc.. (3/7/23). "Press Release: Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay". Fremont, CA....
• [10] Capitainer AB. (1/30/23). "Press Release: Capitainer Announces Collaboration with AstraZeneca". Stockholm....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2023. Made in Germany.